Outlook Therapeutics, Inc. (OTLK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Robert Charles Jahr
|
President, CEO & Director | 603.06k | -- | 1973 |
|
Mr. Kevin Lundquist
|
CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | -- | -- | 1968 |
|
Mr. Joel Prieve
|
Senior Vice President of Licensing and M&A | -- | -- | -- |
|
Dr. Surendra Sharma M.D.
|
Senior Vice President of Medical Affairs | -- | -- | -- |
|
Dr. Jennifer M. Kissner Ph.D.
|
Senior Vice President of Clinical Development & Regulatory Affairs | -- | -- | -- |
|
Mr. Jedd Comiskey
|
Senior VP - Head of Europe | -- | -- | -- |
|
Mr. Greg DiPasquale
|
Chief Commercial Officer | -- | -- | -- |
Outlook Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 17
Description
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Corporate Governance
Upcoming Events
December 18, 2026 at 1:30 PM UTC
Outlook Therapeutics, Inc. Earnings Date
